Ulinastatin Reduces the Severity of Intestinal Damage in the Neonatal Rat Model of Necrotizing Enterocolitis

• DOI: 10.12659/msm.919413
• Publication Date: 2019-12-02T11:00:08Z
• Authors: Shuxia Liang; Panjian Lai; Xiaobing Li; Jie Xu; Yunguang Bao; Yuanshu Fang; Mingxing Ding
• Keywords: Ulinastatin; Necrotizing Enterocolitis; Enterocolitis

BACKGROUND:Ulinastatin is a protease inhibitor derived from urine that has shown anti-inflammatory effects in human disease, including sepsis. Necrotizing enterocolitis (NEC) common gastrointestinal disease premature infants. Our aim was to explore the of ulinastatin on neonatal NEC rat model. MATERIAL AND METHODS:Forty-five rats were divided into 3 groups: normal control; NEC+sepsis-induced kidney injury (SIRS); NEC/SIRS+ulinastatin. The NEC/SIRS model induced by injection intraperitoneal saline, enteral formula feeding, hypoxia-hyperoxide, and cold stress exposure. perfused with at dose 10 000 u/kg/day. Giemsa staining hematoxylin eosin (H&E) performed evaluate severity intestinal damage. To assess cell apoptosis, we examined expression caspase-3 TUNEL western blot analysis. Intestinal levels inflammatory cytokines (IL-1β, IL-6, TNF-α) using ELISA assay. RESULTS:Rats treated group had better physiological status histological score compared group. Ulinastatin reduced NEC-induced weight loss. Macroscopic microscopic morphology analyses showed lower damage detection results revealed significantly inhibited apoptosis NEC. Furthermore, decreased IL-1β, TNF-α CONCLUSIONS:Ulinastatin could ameliorate possess anti-apoptosis anti-inflammation effects.